Paradigm Therapeutics

Paradigm Therapeutics is a biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, including orphan products.

Our Mission

Paradigm Therapeutics is dedicated to developing innovative therapies for people living with rare diseases, including Epidermolysis Bullosa (EB), a devastating disorder for which there is no effective treatment.

Debra International EB Picture

Meet Our Team

Dr. Robert Ryan, Founder and Chief Executive Officer

Dr. Robert Ryan is currently the CEO of Paradigm Therapeutics, which is a biotech based in South Carolina focused on the development of therapies for the treatment of diseases which have a high unmet need, including orphan indications. Dr. Ryan was previously CEO and co-founder of Scioderm, which is a company that developed a topical therapy for Epidermolysis Bullosa. Dr. Robert Ryan has more than 30 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV in many therapeutic areas including oncology, infectious diseases, GI and metabolic diseases, pain, neurology, dermatology, respiratory, and cardiovascular. Dr. Ryan previously held senior regulatory positions at PPD, INC Research, and Quintiles, in addition to senior preclinical, program management and clinical positions with Roche, Bristol-Myers Squibb (BMS), Celtic Pharma, UCB, Atherogenics, and Pfizer. Dr. Ryan has had direct development involvement resulting in approval of over 20 drug candidates across various therapeutic areas.

Dr. Ron Nardi, Executive VP Development

Dr. Nardi has broad therapeutic experience as a Research and Development Executive having spent more than 35 years involved across the spectrum of drug discovery and drug development responsibilities from target identification through clinical pharmacology, clinical development and global regulatory affairs including multiple drug approvals in several therapeutic categories. Prior to his experience at Paradigm Therapeutics, he served in various senior positions at Scioderm, the International Partnership for Microbicides, and Ferring Pharmaceuticals. Earlier in his career he managed discovery research activities in several large pharmaceutical companies including Glaxo, and Warner-Lambert Pharmaceutical Research. Dr. Nardi has a Ph.D in pharmacology and toxicology.

Dr. Nardi has experience in multiple therapeutic categories including cardiovascular diseases (CAD and heart failure), gastrointestinal disease (IBD, ulcer disease, GERD), endocrinology (infertility, brain-gut peptides) and oncology (prostate, sarcomas).

Michael Zimmer Headshot

Michael Zimmer is a highly experienced executive who brings 30 years of experience as a business leader in various roles including Finance, Accounting, Operations, Supply Chain, Business and Employee Development. He is the Past CFO and President / CEO for ARIES ALLIANCE Company with global operations in the U.S., France, UK, Canada, Russia, Singapore, China and Japan. Mr. Zimmer worked for Price Waterhouse Coopers in Auditing and Consulting and brings experience with M&A and MBO transactions, IPO transactions, Bank Financing, Capital Acquisitions, Site Selection and Incentive Plans, and Negotiations.

Willistine Lenon, Executive VP Clinical Operations

Willistine Lenon has more than 34 years of clinical operation experience in the pharmaceutical/ contract research organization (CRO) industries globally including conducting of trials in the US, Canada, Latin America, Europe, Australia, and Pan-Asia. Ms. Lenon’s therapeutic expertise in clinical trials is broad in areas including Oncology, Dermatology, Analgesia, Cardiovascular, Genitourinary, hematology, Metabolic Disorders, Neurology, Ophthalmology, Pulmonary/Allergy, and Rheumatology.

Steve Cole, Head of Business Development

Mr. Cole has broad experience in the pharmaceutical industry having held management positions at Abbott Laboratories, G.D. Searle, and A.H. Robins. He was also Head of the Far Eastern section of the PMA. He lived in Japan and his consulting company has done numerous licensing and acquisition deals. Mr. Cole has served as a director for a number of companies and in a corporate governance and audit committee as a financial expert for a publicly traded company.

Mr. Cole graduated from the University of Wisconsin in 1957. After serving as an officer in the United States Army, he received a master’s degree from the American Graduate School for International Business following graduate studies at the University of Michigan.

Heather Howard, Director Operations

Heather Howard, Director of Operations, has broad experience setting up new businesses, including managing and oversight of employees within her last company. In addition, Heather has previously worked on research projects along with assisting in fundraising efforts for other biotech companies including Innova Therapeutics and Cavalry Therapeutics. Heather’s role at Paradigm Therapeutics will include oversight of office activities including organizing office operations and procedures, designing and maintaining filing systems to support clinical operations and corporate information, managing databases, and overseeing company events and conferences.

Mrs. Howard received her BS from the College of Charleston and her MPT from the Medical University of South Carolina.

Paradigm Therapeutics logo - Partner in Rare Diseases

Copyright © 2024 Paradigm Therapeutics. All Rights Reserved.


Website by  Creare Web Solutions

Thanks for your interest in Zorblisa™

Please tell us who you are so we can keep you updated on the future of treatments for EB.